RedHill Biopharma Ltd (RDHL)

[DorseyE]

Statement from the article....

“ Top-line data from the U.S. Phase 2 study of orally administered opaganib in patients with severe COVID-19, evaluating safety and potential efficacy signals, is expected later this month following the last patient’s last dose administered on November 26”